Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
EyePoint Pharmaceuticals Inc
EYPT | US
15.67
USD-0.08
-0.51%
EYPT | US
Loading StockChartView...
About EyePoint Pharmaceuticals Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
09/03/2026
Close
15.67
Open
15.56
High
15.84
Low
15.05
EyePoint Pharmaceuticals Inc. a pharmaceutical company engages in developing and commercializing therapeutics to enhance the lives of patients with serious eye disorders in the United States China and the United Kingdom. Its commercial products include YUTIQ for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU for the treatment of postoperative inflammation. The company's pipeline leverages its Durasert technology for sustained intraocular drug delivery including EYP-1901 an investigational sustained delivery intravitreal treatment that is in Phase 2 clinical trials. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals Inc. in March 2018. EyePoint Pharmaceuticals Inc. was incorporated in 1987 and is headquartered in Watertown Massachusetts.
View LessEYPT | US
Risk
93.5
Sharpe
1.65
Luna's Score
49/100
Recommendation
Hold
Luna says (EYPT | US)
What's Working
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Strong Sharpe Ratio (> 1.2)
What's not Working
Price Below SMA10D
High Short-term Volatility
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
High Short percentage (> 15%)
Weak Operating Margin (< 10%)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
Loading RiskMeterView...
10 days
90.6%1 month
93.5%3 months
69.5%6 months
71.4%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
2.59
Debt to equity
0.10
Debt to assets
0.07
Ent. to EBITDA
-11.49
Ent. to rev.
6.64
PEG
-
Other Fundamentals
EBITDA
-96.53M
MarketCap
838.63M
MarketCap(USD)
838.63M
Div. yield
-
Op. margin
-364.52
Erngs. growth
-
Rev. growth
4.10
Ret. on equity
-60.81
Short ratio
14.75
Short perc.
19.56
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
3.86
Range1M
6.53
Range3M
7.00
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
0.74
Price X volume
22.38M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -11.49 | 0.53 | Cheaper |
| Ent. to Revenue | 6.64 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 2.59 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 69.51 | 72.80 | Par |
| Debt to Equity | 0.10 | -1.23 | Expensive |
| Debt to Assets | 0.07 | 0.25 | Cheaper |
| Market Cap | 838.63M | 3.66B | Emerging |
